Complete Genomics Well Positioned To Move From Research To Clinical In Genome Sequencing

Rod Raynovich submits:The IPO market is setting up for continued investor interest in the biotech sector.

Prohost Biotech submits:In June 2009, Illumina (ILMN) announced the launch of its individual genome sequencing service. The service is built around physician-patient consultation, with a physician’s order required to initiate the process.

By Medhanie:We knew the likelihood of Complete Genomics (GNOM) remaining an independent company was low. Given its low trading price, difficulty in gaining access to capital and its pending lawsuit with Illumina (ILMN), a sale almost seems inevitable.

By OneMedPlace: By Herina Ayot Keating Capital’s President Timothy Keating was interviewed by OneMedRadio where he describes the liquidity premium that gives public companies 3x valuation over private company peers and the dramatic decline in IPOs and increase in size that is debilitating economic growth.Click to hear audio and see below for a full transcript.

By Grant Zeng: Rosetta Genomics (ROSG) is an Israel-based molecular diagnostic company focused on developing and commercializing molecular diagnostics for cancers.

VASCO Data Security International, Inc. (VDSI) Q2 2013 Earnings Conference Call July 25, 2013, 10:00 AM ET Executives Kendall Hunt - Founder, Chairman and Chief Executive Officer Jan Valcke - President and Chief Operating Officer Clifford Bown - Executive Vice President and Chief Financial Officer Jochem Binst - Director, Corporate Communications Analysts

Rosetta Genomics Ltd. (ROSG) Business Update Conference Call October 2, 2012 10:00 a.m. ET Executives Kenneth Berlin - President and Chief Executive Officer Ron Kalfus - Chief Financial Officer Anne Marie Fields - Investor Relations, LHA Presentation Operator

The Burrill Report submits: By Marie DaghlianDNA sequencing firm Complete Genomics (GNOM) went public after scaling back its deal price more than 30 percent to get it done. Shares began trading on the Nasdaq Global Market on Thursday under the symbol GNOM. The stock closed at $8.03, down more than 10 percent on the first day of trading with volume of nearly 2.5 million shares.